40
nanotimes
Companies Facts
N
anoViricides, Inc. (OTC BB: NNVC.OB) reports that post-infection treatment with its optimized
FluCide™ drug candidates resulted in dramatic red- uction in the number of lung lesions that are caused by a lethal influenza virus infection. These findings were seen in the most recent H1N1 influenza animal study. Four days post virus infection, animals treated with three of the optimized FluCide™ nanoviricide drug candidates exhibited greater than 95% reduc- tion in the number of lung lesions as compared to the infected yet untreated control animals (p-values < 0.001). In contrast, animals treated with Oseltami- vir (Tamiflu®
, Roche) showed only a 50% reduction.
In another significant finding, no increase in the number or size of the lung lesions was observed over the entire duration of the study in the FluCide™- treated animals. This was not the case for the Oselta- mivir-treated animals. This demonstrated that treat- ment with FluCide drug candidates provided clear and strong protection against lung damage caused by the severe influenza infection.
The studies were conducted by Dr. Krishna Menon, PhD, VMD, MRCS, at KARD Scientific, MA. One million virus particles of Influenza A Strain A/WS/33 (H1N1) were aspirated directly into the lungs of mice. The same quantity of virus infection was repea- ted at 22 hrs. This influenza model was designed to be uniformly fatal in 100% of the infected, untreated animals within 5 days after infection. Treatment with the FluCide candidates and Oseltamivir commenced 24 hours after the first viral infection. The duration of study was 21 days.
The Company had previously reported that the same three optimized FluCide™ nanoviricide drug candi-
dates achieved significantly increased survival (20.2 to 22.2 days) as compared to animals treated with Oseltamivir (only 8.3 day survival). The lung histology (microscopic tissue examination) data show that the observed increase in survival was accompanied by a dramatic reduction in virus-induced lung inflammati- on and necrosis.
http://www.nanoviricides.com
T
exas Instruments Incorporated (TI; NYSE: TXN) and National Semiconductor (NYSE: NSM)
have signed a definitive agreement under which TI will acquire National for $25 per share in an all- cash transaction of about $6.5 billion. The acquisi- tion combines two industry leaders in analog semi- conductors, each with unique strengths in delivering products to improve performance and efficiency and convert real-world signals in electronic systems. The boards of directors of both companies have unani- mously approved the transaction.
National Semiconductor Corp. introduced a pair of high-current, synchronous buck regulators with the industry’s highest efficiency at 97 percent. The LM21212-1 and LM21215 are well-suited for high- performance FPGAs, ASICs and microprocessors used in a variety of low-voltage applications including wireless, networking and optical communications infrastructure. National’s new buck regulators are available now and offered in 20-pin thermally- enhanced TSSOP packages. Priced in quantities of 1,000, the LM21212-1 is $3.85 and the LM21215 is $4.15. A version of the LM21212-1 with adjustable switching frequency will be available in March 2011.
http://www.national.com/pf/LM/LM21212-1.html
http://www.national.com/pf/LM/LM21215.html
11-02/03 :: February / March 2011
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80 |
Page 81 |
Page 82 |
Page 83 |
Page 84 |
Page 85 |
Page 86 |
Page 87 |
Page 88 |
Page 89 |
Page 90 |
Page 91 |
Page 92 |
Page 93 |
Page 94 |
Page 95